PXS.ASX
Pharmaxis secures US FDA approval for Bronchitol, sales to bankroll development of myelofibrosis drug candidate
In what has been described as a “transformational step” Pharmaxis (ASX: PXS) has collared United States Food and Drug Administration approval for its Bronchitol drug (mannitol) to be used in the country as an adjunct therapy for cystic fibrosis patients. The green light from the FDA means Pharmaxis can sell Bronchitol, which is an inhalable […]
Pharmaxis takes firm steps towards commercialising suite of fibrotic disease treatments
Pharmaceutical company Pharmaxis (ASX: PXS) has taken another step towards developing a useful treatment for debilitating fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF), after announcing positive results from its Phase 1 clinical trial. The trial investigated the safety profile for the second of its ‘Lysyl Oxidase Like 2’ (LOXL2) inhibitor […]
Pharmaxis Phase 1 clinical trial proves safety of new LOXL2 drug in fibrotic disease treatment
Pharmaceutical company Pharmaxis (ASX: PXS) has returned positive results from a Phase 1 clinical trial for the first of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as non‐alcoholic steatohepatitis and idiopathic pulmonary fibrosis. The double-blind placebo trial confirmed the “excellent drug like properties” demonstrated in earlier pre‐clinical […]
